Stock Market News 2025-10-24
321 news published.
Biotech headlines and strategic deals
Eli Lilly (LLY) remains in focus after its move to buy Adverum Biotechnologies, reinforcing Lilly’s push into gene therapy and reshaping expectations for rare‑disease and ophthalmology programs.
Biogen (BIIB) broadened its immunology pipeline by licensing an oral C5aR1 antagonist from Vanqua Bio — a deal that could speed time‑to‑market for complement‑related assets: announcement.
Syndax (SNDX) won FDA approval for Revuforj® (revumenib), a regulatory milestone that immediately alters commercial and valuation outlooks for a targeted AML therapy.
Zai Lab (ZLAB) updated Phase 1 data for zocilurtatug pelitecan (ZL‑1310), supporting its DLL3‑targeted ADC program and launching a global Phase 3 registrational study for small‑cell lung cancer.
Elanco (ELAN) scored an unusual regulatory win: Credelio™ (lotilaner) received an FDA Emergency Use Authorization
Clinical data and conference reads
Xencor (XNCR) presented initial data for XmAb819, a first‑in‑class ENPP3 x CD3 bispecific for clear‑cell renal cell carcinoma — early signals that could validate a new T‑cell engager approach in solid tumors.
Merus (MRUS) reported interim data for petosemtamab in metastatic colorectal cancer that showed monotherapy activity and stronger responses when combined with FOLFOX/FOLFIRI — results that could influence partner interest and trial design: data note.
PMV Pharmaceuticals (PMVP) and Arvinas (ARVN) each shared conference updates that matter for mutation‑targeted and degrader‑based oncology strategies: rezatapopt interim data, ARV‑806 preclinical work.
Capital markets, M&A and balance‑sheet moves
Plymouth Industrial REIT (PLYM) agreed to be acquired by Makarora in a deal valued at $2.1 billion, marking a sizeable industrial‑REIT consolidation and offering a definitive take‑private path for shareholders: deal terms.
Mural Oncology (MURA) shareholders approved the proposed acquisition by XOMA Royalty’s subsidiary XRA 5 Corp., advancing a strategic exit that will change ownership and potential royalty economics for Mural assets.
SEI (SEIC) boosted its share‑repurchase authorization by $650 million, a capital‑allocation move that signals confidence in free‑cash‑flow and can be accretive to EPS over time: program increase.
X4 Pharmaceuticals (XFOR) priced an underwritten offering of $135 million, extending runway for late‑stage programs while adding near‑term dilution: official notice.
Grindr (GRND) updated its process as the special committee confirmed receipt of a take‑private proposal from large shareholders; that follows earlier reporting of a potential $18.00 per‑share bid and keeps the company under strategic review: original offer note.
Defense, aerospace and industrial awards
Parsons (PSN) secured a seat on a U.S. Navy integration and logistics support vehicle program with a $10 billion ceiling, a multi‑year services opportunity boosting revenue visibility: read more.
General Dynamics (GD) posted third‑quarter 2025 results that offer insight into prime‑contractor performance and defense spending trends: results.
Lockheed Martin (LMT) reported that the Orion spacecraft completed a major stacking milestone ahead of the Artemis II mission — a schedule update that matters for contractor revenue phasing: milestone.
HII (HII) completed second builder’s sea trials for destroyer Ted Stevens (DDG 128), reducing near‑term delivery risk on a major naval platform.
Borr Drilling (BORR) announced contract terminations, an operational development that bears on utilization and future revenue for offshore drilling peers.
Corporate earnings, sector reads and miners
HCA Healthcare (HCA) and Procter & Gamble (PG) released quarterly reports that investors will parse for utilization, consumer demand and margin dynamics; P&G’s fiscal Q1 is watched for pricing and cost trends: HCA, P&G.
Newmont (NEM) announced commercial production at Ahafo North in Ghana, improving free‑cash‑flow visibility for one of the largest gold producers.
AI infrastructure, fintech and corporate tech wins
SuperX (SUPX) invested in an NVIDIA solution provider, MicroInference, linking hardware acceleration to thermal management — a sign that investors remain focused on infrastructure scaling for AI workloads: investment note.
Pega (PEGA) was named a leader in Gartner’s Magic Quadrant and highlighted in the Critical Capabilities report for business orchestration and automation — recognition that can support enterprise sales momentum: report.
Salesforce (CRM) granted equity awards under an inducement plan, a retention step that underscores competition for AI and cloud engineering talent: details.
Crypto, mining and selected financings
Core Scientific (CORZ) released fiscal 3Q25 results, an update investors will weigh for operational recovery amid bitcoin price swings.
Allied Gold (AAUC) closed a C$175 million marketed equity offering to shore up project financing and reduce execution risk on mine development: details.
Regulatory, listings and smaller corporate notices
Cenntro (CENN) was granted a 180‑day extension to meet Nasdaq minimum bid price requirements, buying time to regain compliance: notice.
Theriva Biologics (TOVX) provided a response to unusual market action, a reminder to traders to watch liquidity and corporate communications when volatility spikes.
Selected smaller results and filings
- First Capital (FCAP) reported record quarterly earnings, notable for regional financials and dividend capacity.
- Affinity Bancshares (AFBI) and Manhattan Bridge Capital (LOAN) released third‑quarter results; investors will look at credit trends and yield income: AFBI, LOAN.
Watchlist and upcoming dates
SolarEdge (SEDG) will announce third‑quarter results on November 5 — a key print for solar demand and margin outlooks: read more. VEON (VEON) will report 3Q25 earnings on November 10, a telecom snapshot for ARPU and subscriber trends: notice.
Stay ahead of the market with our list of today's most important stock news and financial updates. Whether you're a day trader, long-term investor, or market enthusiast, our news feed covers everything you need to know about publicly traded companies.
Our news feed is designed for investors who want to stay informed about the latest developments affecting their portfolio or watchlist. Whether you're researching potential investments, monitoring your current holdings, or simply staying up-to-date with market trends, our stock news page provides the information you need to make informed decisions.
What You'll Find on This Page:
- Breaking financial news and market-moving headlines
- FDA approvals and clinical trial results for biotech and pharma stocks
- Stock offerings, dividends, and other corporate actions
- Mergers, acquisitions, and strategic partnerships
- Business news affecting company performance and stock prices
- Easy-to-use tags for quick news categorization
- Stock tickers for instant company identification
- AI sentiment analysis to gauge market reaction
- Estimated impact scores to assess potential stock movement